Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ATAI Life Sciences NV | ATAI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.87 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 1.025 - 2.85 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 1.87 | USD |
ATAI Life Sciences NV Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
310.44M | 166.01M | - | 314k | -40.22M | -0.24 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ATAI Life Sciences NV News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ATAI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.05 | 2.07 | 1.80 | 1.90 | 1,010,280 | -0.18 | -8.78% |
1 Month | 1.805 | 2.85 | 1.76 | 2.29 | 2,529,168 | 0.065 | 3.60% |
3 Months | 1.80 | 2.85 | 1.58 | 2.08 | 1,715,028 | 0.07 | 3.89% |
6 Months | 1.22 | 2.85 | 1.025 | 1.84 | 1,431,493 | 0.65 | 53.28% |
1 Year | 1.95 | 2.85 | 1.025 | 1.82 | 1,097,287 | -0.08 | -4.10% |
3 Years | 21.00 | 22.91 | 1.025 | 3.95 | 978,388 | -19.13 | -91.10% |
5 Years | 2.31 | 22.91 | 1.025 | 3.89 | 869,333 | -0.44 | -19.05% |
ATAI Life Sciences NV Description
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany. |